Clinical Trial

Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease

Study acronym: LidoVOC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-14
notable Primary completion pushed: 2028-03-01 -> 2028-08-03 2026-07-14
minor Completion pushed: 2028-04-01 -> 2028-08-03 2026-07-14
Trial Details
NCT Number NCT07274254
Lead Sponsor Nantes University Hospital
Conditions Vaso-Occlusive Pain Episode in Sickle Cell Disease
Enrollment 104 participants
Start Date 2026-07-03
Primary Completion 2028-08-03 (estimated)
Study Completion 2028-08-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-13